carbamates has been researched along with Fibrosis in 12 studies
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Excerpt | Relevance | Reference |
---|---|---|
" Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis." | 9.34 | Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. ( Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A, 2020) |
" Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis." | 5.34 | Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. ( Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A, 2020) |
"Using data from a phase III clinical trial (GIFT-I) that enrolled Japanese patients with HCV genotype 1b infection, population pharmacokinetic models were developed for the drugs that comprise the 2D regimen: paritaprevir, ombitasvir, and ritonavir." | 2.84 | Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. ( Gopalakrishnan, SM; Khatri, A; Menon, RM; Mensing, S; Polepally, AR, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 4 (33.33) | 2.80 |
Authors | Studies |
---|---|
Lei, H | 2 |
Li, Z | 1 |
Li, T | 2 |
Wu, H | 1 |
Yang, J | 2 |
Yang, X | 2 |
Yang, Y | 2 |
Jiang, N | 1 |
Zhai, X | 2 |
Cao, Z | 1 |
Liu, Z | 1 |
Sun, R | 1 |
Mashaal, AR | 1 |
Abd El-Hameed, M | 1 |
El Ray, AA | 1 |
Mahmoud Diab, T | 1 |
Dawood, RM | 1 |
Shemis, MA | 1 |
Seyam, M | 1 |
Kim, JW | 1 |
Abergel, A | 1 |
Asselah, T | 1 |
Mallat, A | 1 |
Chanteranne, B | 1 |
Faure, F | 1 |
Larrey, D | 1 |
Gournay, J | 1 |
Loustaud-Ratti, V | 1 |
Di Martino, V | 1 |
Fouchard-Hubert, I | 1 |
Pol, S | 1 |
Bailly, F | 1 |
Samuel, D | 1 |
Tran, A | 1 |
Dodel, M | 1 |
Andant, N | 1 |
Lamblin, G | 1 |
Muti, L | 1 |
Reymond, M | 1 |
Teilhet, C | 1 |
Pereira, B | 1 |
Buchard, B | 1 |
Milan, M | 1 |
Pace, V | 1 |
Maiullari, F | 1 |
Chirivì, M | 1 |
Baci, D | 1 |
Maiullari, S | 1 |
Madaro, L | 1 |
Maccari, S | 1 |
Stati, T | 1 |
Marano, G | 1 |
Frati, G | 1 |
Puri, PL | 2 |
De Falco, E | 1 |
Bearzi, C | 1 |
Rizzi, R | 1 |
Consalvi, S | 1 |
Mozzetta, C | 1 |
Bettica, P | 1 |
Germani, M | 1 |
Fiorentini, F | 1 |
Del Bene, F | 1 |
Rocchetti, M | 1 |
Leoni, F | 1 |
Monzani, V | 1 |
Mascagni, P | 1 |
Saccone, V | 1 |
Beinhardt, S | 1 |
Peck-Radosavljevic, M | 1 |
Hofer, H | 1 |
Ferenci, P | 1 |
Saab, S | 1 |
Parisé, H | 1 |
Virabhak, S | 1 |
Wang, A | 1 |
Marx, SE | 1 |
Sanchez Gonzalez, Y | 1 |
Misurski, D | 1 |
Johnson, S | 1 |
Gopalakrishnan, SM | 1 |
Polepally, AR | 1 |
Mensing, S | 1 |
Khatri, A | 1 |
Menon, RM | 1 |
Gross, ML | 1 |
Piecha, G | 1 |
Bierhaus, A | 1 |
Hanke, W | 1 |
Henle, T | 1 |
Schirmacher, P | 1 |
Ritz, E | 1 |
Wang, J | 1 |
Kulkarni, A | 1 |
Chintala, M | 1 |
Fink, LM | 1 |
Hauer-Jensen, M | 1 |
1 review available for carbamates and Fibrosis
Article | Year |
---|---|
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials | 2015 |
2 trials available for carbamates and Fibrosis
Article | Year |
---|---|
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2020 |
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; | 2017 |
9 other studies available for carbamates and Fibrosis
Article | Year |
---|---|
Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model.
Topics: Animals; Carbamates; Disease Models, Animal; Fibrosis; Lung; Mice; Phosphoric Diester Hydrolases; Pi | 2022 |
Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Topics: Bleomycin; Carbamates; Fibrosis; Humans; Phosphoric Diester Hydrolases; Pyridines; Structure-Activit | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combi | 2022 |
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Topics: Antiviral Agents; Carbamates; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazo | 2019 |
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation.
Topics: Animals; Apoptosis; Carbamates; Endothelium; Epithelium; Female; Fibroblasts; Fibrosis; Gene Express | 2018 |
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
Topics: Animals; Carbamates; Cells, Cultured; Exercise Test; Fibrosis; Histone Deacetylase Inhibitors; Human | 2013 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama | 2016 |
Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney.
Topics: Albumins; Ambystoma mexicanum; Animals; Carbamates; Fibrosis; Glycated Serum Albumin; Glycation End | 2011 |
Inhibition of protease-activated receptor 1 ameliorates intestinal radiation mucositis in a preclinical rat model.
Topics: Animals; Benzofurans; Carbamates; Fibrosis; Intestinal Mucosa; Intestine, Small; Male; Mucositis; Pe | 2013 |